Cell Therapy Catapult Signs Major Development Agreement with Asterias
News Oct 20, 2015
The Cell Therapy Catapult has announced the signing of an agreement with Asterias Biotherapeutics Inc. The agreement engages the Cell Therapy Catapult to advance development of a large scale manufacturing processes for AST-VAC2, Asterias’ allogeneic dendritic cell immunotherapy. As a part of the agreement, Asterias will be opening a UK subsidiary and employing staff based in the UK.
The Cell Therapy Catapult will streamline and scale manufacturing processes for Asterias’ AST-VAC2 and its forthcoming phase II clinical trial targeting lung cancer. This will provide support that will enable advanced clinical trials and eventual commercialization of the immunotherapy product.
AST-VAC2 is an allogeneic (non-patient specific) cancer vaccine designed to stimulate patient immune responses to telomerase, which is expressed in over 95% of human cancers but is rarely expressed in normal adult cells. AST-VAC2 is currently being developed towards a Phase I/II trial in lung cancer in collaboration with Cancer Research UK.
Asterias selected the Cell Therapy Catapult because of its depth of expertise in cell therapy and the head start the Cell Therapy Catapult had on the challenge due to its own internal Cell Plasticity Platform Project, which is developing large scale manufacturing processes for pluripotent cells. Asterias believes the Cell Therapy Catapult is an important driver in making the UK an environment that facilitates and supports the development of regenerative medicine products.
As part of the agreement, Asterias plans a UK subsidiary. The subsidiary will provide Asterias with the ability to effectively collaborate with the Cell Therapy Catapult and other major partners in the UK. Asterias also will use the UK operation to play a critical role in contributing to the development of the AST-VAC2 platform and maximizing its value.
“International partnerships are critical for the further development of the UK cell and gene therapy industry. The Cell Therapy Catapult has been instrumental in attracting Asterias, a leading US quoted cell therapy company to the UK,” said Keith Thompson, CEO, the Cell Therapy Catapult. “This is an example of how our core platform projects, which aim to overcome major industry challenges, can be leveraged to promote growth of the UK industry.”
“The establishment of a subsidiary in the UK provides Asterias with the ability to effectively collaborate with the Cell Therapy Catapult at a low cost in the medium term while providing a base from which to grow our AST-VAC2 platform and maximize its value,” said Pedro Lichtinger, chief executive officer, Asterias.
“This collaboration with the Cell Therapy Catapult allows Asterias to accelerate its development of manufacturing processes that will be compatible with the commercial needs of our cell based products,” said Katy Spink Ph.D., chief operating officer, Asterias. “The collaboration also enhances our strategic relationships in the UK, an environment which facilitates and supports the development of regenerative medicine products.”
Horizon Enters into Partnership with Pirbright Institute to Improve Vaccine YieldsNews
Extends Horizon’s biomanufacturing capabilities into vaccine manufacture. Research supported by a grant from the Canadian International Development Research Centre, funded by the Bill and Melinda Gates foundation.READ MORE
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Anti-Malaria Drugs Delivered With CaffeineNews
Many drug delivery systems, such as capsules and tablets, can be difficult to swallow, especially for children. Making delivery systems out of polymer gels is an attractive option, but usually requires hazardous levels of heavy metals to be used. Now, scientists have found a way to build these gels from caffeine molecules.READ MORE
Comments | 0 ADD COMMENT
15th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry
Sep 09 - Sep 12, 2018
CE in the Biotechnology & Pharmaceutical Industries: 20th Symposium on the Practical Applications for the Analysis of Proteins, Nucleotides & Small Molecules
Sep 09 - Sep 12, 2018